Dear Readers
The European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) invite you to participate from June 23 to 25 in CLINAM 7/2014, to be held in Basel, Switzerland.
The 7th European Summit for Clinical Nanomedicine and Targeted Medicine brings together Clinical Nanomedicine and Targeted Medicine in the generic context of Personalized Medicine and offers the international debate on precise, highly effective novel medicine, using nanomedicine and targeted delivery for individualized diagnosis and therapy.
In a recent discussion with Patrick Hunziker, the CSO of the CLINAM-Foundation, we asked ourselves how one could state in one sentence the ethical motivation of people, innovating a field -in our case nanomedicine and targeted medicine. The next morning's email from Patrick Hunziker provided a strikingly simple way of condensing this in a single sentence: "Innovation is driven by those who care and therefore find ways to change the status quo by suited means".
Thus the next summit is the indispensable meeting for all those who care and work for better healthcare and contribute with their knowledge and skills to achieve this goal sooner. As Nanomedicine by definition is one of the most interdisciplinary fields, the summit addresses physicians, nanoscientists with a background in pharmacology, molecular biologists, physicists, chemists, biophysicists, medicine materials scientists and engineers, those who make new tools for nanomedicine, policymakers, experts from industry in the field of life sciences, patient organizations as well as the regulatory authorities as the last and most critical entity in the pathway of translation from a finding to its application in man.
In past decades, biotechnology, systems biology and nanomedicine have developed on separate paths, but it is increasingly evident that in combination they are of particular benefit to clinical medicine: We see the rapidly growing technologies and applications which together develop medicine that originates at the molecular, nanoscale and cellular level and will eventually lead to personalized medicine, customized on patient groups and ultimately individuals via molecular profiling. The progress to the "medicine of the future" and towards individualized medicine is well underway and what is "cutting edge technology" today will in the next decades become standard.
After last year's summit which had nearly 500 participants, exciting presentations, lively debates and many in-depth discussions and 140 poster sessions, the fortcoming summit will include the same (see programme under www.clinam.org) with many outstanding speakers. The meeting will be opened by the Nobel Laureate Prof. Aaron Ciechanover MD, speaking on the topic "The ubiquitin system and destruction of our own proteins: from basic mechanisms, through pathogenesis of human diseases and onto their drug targeting". He will show how nanomedicine relates to personalized medicine. Then clinicians will address today's unsolved problems in inflammation, cancer and neurodegenerative diseases followed by more than 100 presentations about how nanomedicine and targeted medicine can progress to a more gentle, precise therapy with less side effects to the benefit of patients and mankind. Among the topics that will be addressed in Basel are: -20 late breaking and ongoing trial results of drugs and devices, -the perspectives on targeting and implications for personalized medicine, -challenges in the nanoparticle-host interaction, -nanomaterial interactions with and in biological systems, -sessions on toxicology in targeted medicine and nanomedicine, -interaction between nanomedicines and the immune system, -nanomedicine in neglected diseases, -diagnostics and therapy, -key characterization methods for nanomedicine applications, -nanomedicine for neurodegenerative and -European Research Council-related talks on nanomedicine and drug delivery.
Nanomedicine is becoming more and more important for industry. Accordingly, many companies are participating in this summit, such as Astra-Zeneca, Celgene
